Increased expression of MicroRNA-21 and its association with chemotherapeutic response in human colorectal cancer

Journal of International Medical Research

Volumn 39, Issue 6, 2011, Pages 2288-2295

  Liu, K ^a   Li, G ^a   Fan, C ^a   Zhou, X ^a   Wu, B ^a   Li, J ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Cell differentiation; Colorectal cancer; Microrna 21 (miR 21); Preoperative chemotherapy; Real time reverse transcription polymerase chain reaction; TNM stage; Tumour response

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MICRORNA 21; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 84555170195     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900626     Document Type: Article

References (37)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Ong SY: Neoadjuvant chemotherapy in the management of colorectal metastases: a review of the literature. Ann Acad Med Singapore 2003; 32: 205-211.
3. Wilke HJ, Van Cutsem E: Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol 2003; 14(suppl 2): ii49-ii55.
4. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Song B, Wang Y, Xi Y, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-4074.
6. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
7. Winter J, Jung S, Keller S, et al: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234.
8. Berezikov E, Guryev V, van de Belt J, et al: Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120: 21-24.
9. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
10. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102: 13944-13949.
11. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-647.
12. Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159.
13. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009; 113: 249-255.
14. Ji Q, Hao X, Meng Y, et al: Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
15. Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68: 10307-10314.
16. Chan SH, Wu CW, Li AF, et al: miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res 2008; 28: 907-911.
17. Roldo C, Missiaglia E, Hagan JP, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-4684.
18. Slaby O, Svoboda M, Fabian P, et al: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (Williston Park) 2007; 72: 397-402.
19. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
20. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257-2261.
21. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human lioblastoma cells. Cancer Res 2005; 65: 6029-6033.
22. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-8707.
23. Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-2129.
24. Markou A, Tsaroucha EG, Kaklamanis L, et al: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008; 54: 1696-1704.
25. Feber A, Xi L, Luketich JD, et al: MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135: 255-260.
26. Tran N, McLean T, Zhang X, et al: MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007; 358: 12-17.
27. Meng F, Henson R, Wehbe-Janek H, et al: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658.
28. Beahrs OH, Henson DE, Hutter RVP, et al (eds): Manual for Staging of Cancer, 4th edn. Chicago: American Joint Committee on Cancer, American Cancer, Philadelphia: JB Lippincott, 1992; pp 75-80.
29. Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675.
30. Becker K, Mueller JD, Schulmacher C, et al: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
31. Hwang JH, Voortman J, Giovannetti E, et al: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
32. Zhang Z, Li Z, Gao C, et al: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 2008; 88: 1358-1366.
33. Hiyoshi Y, Kamohara H, Karashima R, et al: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915-1922.
34. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6: 60.
35. Wu X, Xiao H: miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009; 52: 797-801.
36. Si ML, Zhu S, Wu H, et al: miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803.
37. Li Y, Li W, Yang Y, et al: MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009; 1286: 13-18.